MA55751B1 - Composés de 4h-pyrrolo[3,2-c]pyridin-4-one - Google Patents
Composés de 4h-pyrrolo[3,2-c]pyridin-4-oneInfo
- Publication number
- MA55751B1 MA55751B1 MA55751A MA55751A MA55751B1 MA 55751 B1 MA55751 B1 MA 55751B1 MA 55751 A MA55751 A MA 55751A MA 55751 A MA55751 A MA 55751A MA 55751 B1 MA55751 B1 MA 55751B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- pyrrolo
- pyridin
- processes
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne des composés de formule (I), des procédés pour leur production et leur utilisation en tant que produits pharmaceutiques.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838051P | 2019-04-24 | 2019-04-24 | |
| US201962940036P | 2019-11-25 | 2019-11-25 | |
| EP20721196.2A EP3959211B1 (fr) | 2019-04-24 | 2020-04-22 | Composés de 4h-pyrrolo[3,2-c]pyridin-4-one |
| PCT/EP2020/061176 WO2020216781A1 (fr) | 2019-04-24 | 2020-04-22 | Composés de 4h-pyrrolo[3,2-c]pyridin-4-one |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA55751A MA55751A (fr) | 2022-03-02 |
| MA55751B1 true MA55751B1 (fr) | 2026-04-30 |
Family
ID=70456765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA55751A MA55751B1 (fr) | 2019-04-24 | 2020-04-22 | Composés de 4h-pyrrolo[3,2-c]pyridin-4-one |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US12679836B2 (fr) |
| EP (1) | EP3959211B1 (fr) |
| JP (1) | JP7641913B2 (fr) |
| KR (1) | KR102915019B1 (fr) |
| CN (3) | CN114127064B (fr) |
| AU (1) | AU2020262221B2 (fr) |
| BR (1) | BR112021019998B1 (fr) |
| CA (1) | CA3137218A1 (fr) |
| CL (1) | CL2021002770A1 (fr) |
| CO (1) | CO2021014022A2 (fr) |
| CR (1) | CR20210530A (fr) |
| DK (1) | DK3959211T3 (fr) |
| DO (1) | DOP2021000216A (fr) |
| EC (1) | ECSP21077614A (fr) |
| ES (1) | ES3068321T3 (fr) |
| FI (1) | FI3959211T3 (fr) |
| GE (2) | GEAP202415804A (fr) |
| HR (1) | HRP20260409T1 (fr) |
| IL (1) | IL287390B2 (fr) |
| JO (1) | JOP20210285A1 (fr) |
| LT (1) | LT3959211T (fr) |
| MA (1) | MA55751B1 (fr) |
| MX (1) | MX2021012987A (fr) |
| PE (1) | PE20220254A1 (fr) |
| PH (1) | PH12021552693A1 (fr) |
| PL (1) | PL3959211T3 (fr) |
| PT (1) | PT3959211T (fr) |
| RS (1) | RS68081B1 (fr) |
| SG (1) | SG11202111304UA (fr) |
| TW (1) | TWI849114B (fr) |
| UA (1) | UA130453C2 (fr) |
| WO (1) | WO2020216781A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019081486A1 (fr) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Dérivés de 4h-pyrrolo[3,2-c]pyridin-4-one |
| US12403135B2 (en) | 2019-04-24 | 2025-09-02 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CN115836070B (zh) * | 2020-08-10 | 2024-08-09 | 上海和誉生物医药科技有限公司 | 作为egfr抑制剂的稠环化合物及其制备方法和应用 |
| MX2023003362A (es) * | 2020-09-23 | 2023-05-30 | Scorpion Therapeutics Inc | Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer. |
| WO2022094271A1 (fr) * | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Méthodes de traitement du cancer |
| WO2022098992A1 (fr) * | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Utilisation de composés macrocycliques dans des méthodes de traitement de cancer |
| EP4244225B1 (fr) * | 2020-11-11 | 2026-06-03 | Bayer Aktiengesellschaft | Dérivés de n-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl}oxy)éthyl]prop-2-énamide et composés similaires en tant qu'inhibiteurs d'egfr pour le traitement du cancer |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| JP2024517808A (ja) * | 2021-05-06 | 2024-04-23 | セルジーン コーポレーション | Ｎ－（（ｒ）－１－（３－クロロピリジン－２－イル）－２，２，２－トリフルオロエチル）－２－（（ｓ）－２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－カルボキサミドによる治療方法 |
| IL315739A (en) * | 2022-03-24 | 2024-11-01 | Scorpion Therapeutics Inc | Methods of synthesizing egfr inhibitors |
| WO2023205595A2 (fr) * | 2022-04-20 | 2023-10-26 | Celyn Therapeutics, Inc | Inhibiteurs d'egfr dans le traitement du cancer |
| CA3270236A1 (en) | 2024-08-28 | 2026-04-10 | Bayer Aktiengesellschaft | Stable solid pharmaceutical dosage form comprising crystalline form of her2/mutegfr inhibitor and process for its preparation |
| CA3270230A1 (en) | 2024-08-28 | 2026-04-10 | Bayer Aktiengesellschaft | Crystalline forms of her2/mutegfr inhibitors and process for their preparation |
| CN119264091B (zh) * | 2024-09-04 | 2025-05-27 | 康龙化成手性医药技术(宁波)有限公司 | 一种1,5-双取代-3-氧杂双环[3.1.1]庚烷的合成方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US6673908B1 (en) * | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| US7211573B2 (en) | 2004-12-08 | 2007-05-01 | Hoffmann-La Roche Inc. | Malonamide derivatives |
| DE102006033140A1 (de) | 2006-07-18 | 2008-01-24 | Merck Patent Gmbh | Aminoindazolharnstoffderivate |
| JP2008291023A (ja) | 2007-04-27 | 2008-12-04 | Sumitomo Chemical Co Ltd | アミド化合物とその用途 |
| EP2188292B1 (fr) | 2007-08-08 | 2013-05-29 | GlaxoSmithKline Intellectual Property Development Limited | Dérivés de 2-[(2-{phénylamino}-1h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]benzamide en tant qu'inhibiteur d'igf-1r pour le traitement du cancer |
| CN101367801B (zh) | 2007-08-15 | 2011-01-12 | 上海恒瑞医药有限公司 | 吡咯并六元n杂环羟基吗啡啉类衍生物的制备方法及其在医药上的应用 |
| TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| EP3045457B1 (fr) | 2009-06-15 | 2018-05-09 | Nerviano Medical Sciences S.r.l. | Dérivés de pyrimidinylpyrrolopyridinone substitués, leur procédé de préparation et leur utilisation en tant qu'inhibiteurs de kinase |
| EP2675440B1 (fr) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Inhibiteurs de cystéine protéases, les cathepsines |
| EP2976336A1 (fr) | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Indazoles 3-hétéroaryle substituées |
| AR097325A1 (es) | 2013-08-13 | 2016-03-09 | Gruenenthal Gmbh | Pirroles anillados |
| SMT202000133T1 (it) | 2014-04-23 | 2020-05-08 | Incyte Corp | 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet |
| US20170166598A1 (en) | 2014-05-13 | 2017-06-15 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| TW201613886A (en) | 2014-06-17 | 2016-04-16 | Bayer Pharma AG | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| ES2722431T3 (es) | 2014-12-08 | 2019-08-12 | Bayer Pharma AG | Novedosos compuestos de aril-cianoguanidina |
| WO2016100166A1 (fr) | 2014-12-15 | 2016-06-23 | Bristol-Myers Squibb Company | Dihydro-1h-pyrrolo[3,2-c]pyridin-4(5h)-ones substituées en tant qu'inhibiteurs de ripk3 |
| CN107406417B (zh) * | 2015-01-28 | 2020-06-09 | 拜耳制药股份公司 | 4H-吡咯并[3,2-c]吡啶-4-酮衍生物 |
| WO2016185333A1 (fr) | 2015-05-15 | 2016-11-24 | Novartis Ag | Méthodes de traitement de cancers associés à des formes mutantes de l'egfr |
| WO2019081486A1 (fr) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Dérivés de 4h-pyrrolo[3,2-c]pyridin-4-one |
| US12403135B2 (en) | 2019-04-24 | 2025-09-02 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CA3137610A1 (fr) | 2019-04-24 | 2020-10-29 | Bayer Aktiengesellschaft | Composes de 4h-pyrrolo[3,2-c]pyridin-4-one |
| CA3177214A1 (fr) | 2020-03-31 | 2021-10-07 | Bayer Aktiengesellschaft | Derives de 3-(anilino)-2-[3-(3-alcoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo [3,2-c] pyridin-4-one en tant qu'inhibiteurs d'egfr pour le traitement du cancer |
-
2020
- 2020-04-22 KR KR1020217037778A patent/KR102915019B1/ko active Active
- 2020-04-22 ES ES20721196T patent/ES3068321T3/es active Active
- 2020-04-22 IL IL287390A patent/IL287390B2/en unknown
- 2020-04-22 PH PH1/2021/552693A patent/PH12021552693A1/en unknown
- 2020-04-22 FI FIEP20721196.2T patent/FI3959211T3/fi active
- 2020-04-22 CA CA3137218A patent/CA3137218A1/fr active Pending
- 2020-04-22 GE GEAP202415804A patent/GEAP202415804A/en unknown
- 2020-04-22 MA MA55751A patent/MA55751B1/fr unknown
- 2020-04-22 CN CN202080031189.4A patent/CN114127064B/zh active Active
- 2020-04-22 MX MX2021012987A patent/MX2021012987A/es unknown
- 2020-04-22 AU AU2020262221A patent/AU2020262221B2/en active Active
- 2020-04-22 EP EP20721196.2A patent/EP3959211B1/fr active Active
- 2020-04-22 HR HRP20260409TT patent/HRP20260409T1/hr unknown
- 2020-04-22 RS RS20260467A patent/RS68081B1/sr unknown
- 2020-04-22 CR CR20210530A patent/CR20210530A/es unknown
- 2020-04-22 LT LTEPPCT/EP2020/061176T patent/LT3959211T/lt unknown
- 2020-04-22 US US17/605,975 patent/US12679836B2/en active Active
- 2020-04-22 CN CN202311716707.8A patent/CN117986251A/zh active Pending
- 2020-04-22 CN CN202311714944.0A patent/CN117946100A/zh active Pending
- 2020-04-22 TW TW109113538A patent/TWI849114B/zh active
- 2020-04-22 PT PT207211962T patent/PT3959211T/pt unknown
- 2020-04-22 PL PL20721196.2T patent/PL3959211T3/pl unknown
- 2020-04-22 BR BR112021019998-5A patent/BR112021019998B1/pt active IP Right Grant
- 2020-04-22 WO PCT/EP2020/061176 patent/WO2020216781A1/fr not_active Ceased
- 2020-04-22 JP JP2021563175A patent/JP7641913B2/ja active Active
- 2020-04-22 PE PE2021001760A patent/PE20220254A1/es unknown
- 2020-04-22 DK DK20721196.2T patent/DK3959211T3/da active
- 2020-04-22 GE GEAP202015804A patent/GEP20247648B/en unknown
- 2020-04-22 UA UAA202106517A patent/UA130453C2/uk unknown
- 2020-04-22 SG SG11202111304UA patent/SG11202111304UA/en unknown
- 2020-04-22 JO JOP/2021/0285A patent/JOP20210285A1/ar unknown
-
2021
- 2021-10-19 EC ECSENADI202177614A patent/ECSP21077614A/es unknown
- 2021-10-20 CO CONC2021/0014022A patent/CO2021014022A2/es unknown
- 2021-10-21 CL CL2021002770A patent/CL2021002770A1/es unknown
- 2021-10-22 DO DO2021000216A patent/DOP2021000216A/es unknown
-
2024
- 2024-11-15 US US18/949,801 patent/US20250136599A1/en not_active Abandoned